- Conditions
- Alzheimers Disease
- Interventions
- CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520, Alum
- Biological · Other · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 60 Years to 75 Years
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 78
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 67 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1393–1416
of 33,205
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pain Control
- Interventions
- Gabapentin, Placebos
- Drug
- Lead sponsor
- University of Nevada, Las Vegas
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 219 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Active Transcranial direct current stimulation (tDCS), Sham Transcranial direct current stimulation (tDCS), Auditory Remediation, Control computer activities
- Device · Behavioral
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Autism Spectrum Disorder (ASD)
- Interventions
- Placebo, RO7017773
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 15 Years to 45 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Orlando, Florida + 8 more
- Conditions
- T2DM (Type 2 Diabetes Mellitus)
- Interventions
- Cohort A: ORMD-0801, Placebo oral capsule, Cohort B: ORMD-0801
- Drug
- Lead sponsor
- Oramed, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 373 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Flint, Michigan
- Conditions
- Nerve Block, Pain, Postoperative, Pelvic Floor Disorders, Pelvic Organ Prolapse, Pudendal Neuralgia, Surgery
- Interventions
- Pudendal block
- Procedure
- Lead sponsor
- MetroHealth Medical Center
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Delay in Time to Lactogenesis Stage II
- Interventions
- Depo-Provera Injectable Product, Placebos
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
- Interventions
- Mitapivat, Placebo Matching Mitapivat
- Drug
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Atlanta, Georgia • New York, New York + 2 more
- Conditions
- Cystic Fibrosis
- Interventions
- N6022, Normal saline
- Drug
- Lead sponsor
- Nivalis Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Palo Alto, California + 14 more
- Conditions
- Lateral Canthal Lines, Glabellar Lines
- Interventions
- MT10109L, Placebo
- Drug
- Lead sponsor
- Medy-Tox
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 425 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 11
- States / cities
- Scottsdale, Arizona • Solana Beach, California • Bradenton, Florida + 7 more
- Conditions
- Anxiety Disorder, Depression, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Interventions
- minocycline hydrochloride, placebo, laboratory biomarker analysis, Questionnaire administration
- Drug · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- HIV Infections
- Interventions
- VH4524184, Matching Placebo, Antiretroviral therapy
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 5
- States / cities
- Bakersfield, California • Los Angeles, California • West Hollywood, California + 2 more
- Conditions
- Mild Cognitive Impairment, Prodromal Alzheimer's Disease
- Interventions
- Placebo Oral Tablet, AGB101 220 mg tablet
- Drug
- Lead sponsor
- AgeneBio
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Laguna Hills, California • Oceanside, California + 20 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, Linagliptin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 29
- States / cities
- Escondido, California • Greenbrae, California • Los Angeles, California + 25 more
- Conditions
- Cognitive Change
- Interventions
- Placebo, Origami, Reading
- Behavioral
- Lead sponsor
- University of Kentucky
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Mild Gastrointestinal Symptoms in Healthy Adults
- Interventions
- Bifidobacterium animals subsp. lactis BL04+PreforPro, Bifidobacterium animals subsp. lactis BL04, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Colorado State University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Healthy
- Interventions
- Aspirin 81 mg, Celecoxib 200mg capsule
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- rAAVrh74.MCK.micro-Dystrophin
- Biological
- Lead sponsor
- Jerry R. Mendell
- Other
- Eligibility
- 7 Years and older · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Epilepsy, Tonic-Clonic
- Interventions
- lamotrigine (LAMICTAL) extended-release, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 64
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Northport, Alabama + 56 more
- Conditions
- Alzheimer's Disease
- Interventions
- memantine HCl
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 9
- States / cities
- San Francisco, California • Westminster, California • New Haven, Connecticut + 6 more
- Conditions
- Coronavirus Disease 2019 COVID-19
- Interventions
- TJ003234, Placebo
- Drug
- Lead sponsor
- I-Mab Biopharma US Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • Sylmar, California • Washington D.C., District of Columbia + 10 more
- Conditions
- Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Breast Carcinoma
- Interventions
- Biospecimen Collection, Educational Intervention, Exercise Intervention, Fisetin, Physical Performance Testing, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Other · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 6
- States / cities
- Alhambra, California • Beverly Hills, California • Burbank, California + 3 more
- Conditions
- Efficacy and Safety
- Interventions
- Proxalutamide (GT0918), Placebo
- Drug
- Lead sponsor
- Suzhou Kintor Pharmaceutical Inc,
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 733 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Long Beach, California • Sandy Springs, Georgia + 5 more
- Conditions
- Pain
- Interventions
- Lumbar sympathetic block with Botulinum Toxin type A
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Stanford, California